Literature DB >> 28671305

Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China.

Jie Lu1, Xiaogang Xiang1, Zhujun Cao1, Weijing Wang1, Gangde Zhao1, Weiliang Tang1, Lu Chen1, Simin Guo1, Yan Zhuang1, Dongmei Shi1, Lichang Chen1, Shisan Bao2, Wei Cai1, Hui Wang1, Huijuan Zhou1, Qing Xie1.   

Abstract

The diversity of HCV genotypes is ever-evolving and requires continuous surveillance. The aim of this study was to investigate the dynamics of HCV genotypes, and their associated demographic and clinical patterns in China. By searching computerized hospital information system, a total of 1155 HCV-positive patients eligible for analysis were retrospectively identified from 12 380 consecutive in-patients in the Department of Infectious Diseases, Ruijin Hospital in China between 2009 and 2014. The percentages of HCV genotype 1, 2, 3, or 6 were 61.3%, 12.8%, 18.5%, or 7.4%, respectively. The number of patients hospitalized for HCV infection increased gradually over the study period, particularly those infected by genotype 3 HCV. Patients of genotype 1, 2, 3, or 6 were significantly different. Genotype 1 or two patients were much older, with higher proportion of blood transfusion history. In contrast, genotype 3 or six patients were younger, predominantly male, with more exposure to intravenous drug use. The cirrhosis incidence was higher in genotype 1 or two patients, followed by genotype 3 and six patients. Strikingly, genotype 3 cirrhotic patients were younger, and their estimated infection durations were also shorter, suggestive of a faster disease progression in genotype 3 patients. Multivariate analysis demonstrated that presence of HBcAb was an independent predictor of cirrhosis (OR 2.19, 95%CI 1.27-3.42; P = 0.004). The leading increase and the younger trend of cirrhosis incidence in genotype 3 patients argue for a higher priority to manage the infection in this highly at-risk population.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  China; HCV; cirrhosis; distribution; epidemiology; genotype 3

Mesh:

Substances:

Year:  2017        PMID: 28671305     DOI: 10.1002/jmv.24894

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges.

Authors:  Nianan Luo; Wenjun Zhong; Jiangbin Li; Jianguo Lu; Rui Dong
Journal:  Mol Biol Rep       Date:  2022-08-12       Impact factor: 2.742

2.  High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.

Authors:  Qunying Han; Xiude Fan; Xiaoyun Wang; Ye Wang; Huan Deng; Xiaoge Zhang; Kun Zhang; Na Li; Zhengwen Liu
Journal:  Virol J       Date:  2019-06-03       Impact factor: 4.099

Review 3.  Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China.

Authors:  Qing Xie; Jian-Wei Xuan; Hong Tang; Xiao-Guang Ye; Peng Xu; I-Heng Lee; Shan-Lian Hu
Journal:  World J Hepatol       Date:  2019-05-27

Review 4.  Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China.

Authors:  Xiaozhong Wang; Lai Wei
Journal:  J Clin Transl Hepatol       Date:  2021-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.